The quest for malaria vaccine at the GlaxoSmithKline started in 1984. In collaboration with the non-profit PATH Malaria Vaccine Initiative and funding from Bill & Melinda Gates Foundation, GlaxoSmithKline developed the first malarial vaccine.

1. [DATE]
[COMPANY NAME]
[Company address]
MALARIA VACCINES MARKET - GLOBAL
INDUSTRY INSIGHTS, TRENDS, OUTLOOK,
AND OPPORTUNITY ANALYSIS, 2016-2024

2. Today nearly 40% of the global population is at risk of malaria. According to the World Health Organization
(WHO), there were nearly 214 million malaria cases in 2015 and approximately 4,38,000 malarial deaths
globally. More than 70% of these deaths occur in children under 5 years of age. The Sub-Saharan Africa
carries the highest share of global malaria burden with nearly 89% of malaria cases and 91% of malarial
deaths in 2015. Such high impact of this life threatening disease has brought companies, investors and
non-profit organizations to contribute towards curbing this disease spread. Treatment therapies include
Artemisinin-based combination therapies (ACTs), chloroquine and primaquine. Moreover, recurrence of
this disease has led to drug resistance leading to death of the patient. Therefore, prevention is the major
focus of government, researchers and drug companies. The WHO estimates that increase in the
prevention control and measure has led to a 60% reduction in malaria mortality since 2000.
Mosquirix – the First Malaria Vaccine
The quest for malaria vaccine at the GlaxoSmithKline started in 1984. In collaboration with the non-profit
PATH Malaria Vaccine Initiative and funding from Bill & Melinda Gates Foundation, GlaxoSmithKline
developed the first malarial vaccine.
Browse Report: https://www.coherentmarketinsights.com/ongoing-insight/malaria-vaccines-
market-37
Mosquirix, also known as RTS,S, was in development for about 30 years. Nearly, about USD 565 million
has been invested in developing this vaccine. Bill and Melinda Gates Foundation contributed more than
USD 200 million in this project. Mosquirix received marketing approval from the European authorities in
July 2015. However, the WHO has recommended the Mosquirix vaccine to be examined in a pilot study
before introducing at large scale. The study is carried out in Africa, and has received a funding of USD 25
million from Gavi, a global Vaccine Alliance, bringing together public and private sectors towards a
common goal.
Malaria vaccine seems to be the best solution to prevent the spread of malaria which poses challenges in
terms of drug resistance, and risk of death. Moreover, people use bed nets, and indoor spraying to fight
against the infection. Therefore, there is immense opportunity globally for malaria vaccines in population
at risk - Infants (23 million births annually), pre-adolescent and early adolescent girls, pregnant women in
sub-Saharan Africa, and population in Asia, Latin America, Africa, and Oceania. Furthermore, risk of
transmission of the disease increases from the ‘traveller’ and military population travelling from the U.S.,
Europe, Japan, and Australia, a malaria free zone, to the highly prone developing countries. The global
malaria vaccine market resembles the vaccines market dynamics where the major purchasers being the
health and non-profit organizations.
Get FREE Table of Content: https://www.coherentmarketinsights.com/ongoing-insight/toc/37
More Malaria Vaccines under Development
Mosquirix is a great boon for population in regions which are highly prone to malaria infection. However,
accessibility and low cost of this vaccine is essential to serve the large population in the highly prone
developing regions. Sanaria Inc. is a biotechnology company which aims to develop and commercialize
whole-parasite sporozoite vaccines against Plasmodium falciparum which causes 95% of the malaria
cases. The company is in strong endeavor to make this vaccine available to mass markets as soon as
possible. In addition, Mymetics Corporation, a Switzerland based vaccines developer uses its virosome
Report Description

3. platform technology to develop vaccines. There are two vaccine candidates in its pipeline of which one
cleared the phase 1b clinical rail while the other is in its preclinical stage. Moreover, use of new
technologies such as Nucleic acid vaccines, Proteosomes, and several new adjuvants could generate
next-generation malaria vaccines.
Such global commitments will encourage investors around the world to contribute towards a global malaria
eradication mission.
COMPANY OVERVIEW
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting
our plethora of clients achieve transformational growth by helping them make critical business decisions.
We are headquartered in India, having office at global financial capital in the U.S. Our client base includes
players from across all business verticals in over 150 countries worldwide. We are uniquely positioned to
help businesses around the globe deliver practical and lasting results through various recommendations
about operational improvements, technologies, emerging market trends and new working methods. We
offer both customized and syndicated market research reports that help our clients create visionary growth
plans to provide traction to their business. We meticulously study emerging trends across various
industries at both the global and regional levels to identify new opportunities for our clientele. Our global
team of over 100 research analysts and freelance consultants provide market intelligence from the very
molecular country level and also provide a global perspective of the market. Our team is of the most vital
cog in our robust machinery that gives us the ability to deliver independent insight relying on our cognitive
defusion training module.This allows for an objective and unbiased assessment of the market. We pride
ourselves in my constantly striving to update our extremely in-depth understanding of the market by
closely monitoring and analyzing markets, trends, and emerging best practices, across allfathomable
industries under the sun. This enables us to equip our valued clientele with key decisive inputs to capitalize
on lucrative growth opportunities in the market and to follow firmly position themselves on a high growth
path in the future.
CORPORATE OFFICE:
Coherent Market Insights
303, Astral Court,Above Reliance Fresh,
Near Gaikwad Petrol Pump,
Aundh, Pune – 411045, India
sales@coherentmarketinsights.com
About Us
Contact Us